GH Research’s (GHRS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of GH Research (NASDAQ:GHRS) in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a $40.00 price objective on the stock.

Separately, JMP Securities restated a market outperform rating and set a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Stock Down 2.8 %

Shares of NASDAQ GHRS opened at $8.23 on Thursday. GH Research has a 52-week low of $5.05 and a 52-week high of $14.99. The firm has a market cap of $428.19 million, a price-to-earnings ratio of -13.27 and a beta of 0.83. The company’s 50-day simple moving average is $11.11 and its 200-day simple moving average is $11.22.

GH Research (NASDAQ:GHRS) last released its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Equities research analysts anticipate that GH Research will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

Hedge funds have recently modified their holdings of the business. AdvisorShares Investments LLC raised its holdings in GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after buying an additional 1,977 shares during the period. Lynx1 Capital Management LP increased its position in shares of GH Research by 19.8% during the second quarter. Lynx1 Capital Management LP now owns 3,966,726 shares of the company’s stock valued at $46,252,000 after acquiring an additional 656,163 shares during the last quarter. RA Capital Management L.P. increased its position in shares of GH Research by 11.9% during the first quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock valued at $66,643,000 after acquiring an additional 664,381 shares during the last quarter. Finally, BVF Inc. IL raised its stake in shares of GH Research by 12.1% in the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after acquiring an additional 1,125,000 shares during the period. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).